NOAH welcomes PetMedix into membership
13th June 2023
PetMedix has joined NOAH as an Associate member. Based in Babraham, Cambridge, PetMedix undertakes research and development into monoclonal antibodies for companion animals.
NOAH Chief Executive Dawn Howard said: “We are delighted to welcome PetMedix to NOAH and look forward to working with them. Their cutting-edge work highlights how our sector can contribute to the scientific excellence of the UK, and shows One Health in action, building on human medical research to bring exciting treatment potentials to our pets.”
Tom Weaver, Founder and CEO of Pet Medix said: “As a UK-headquartered animal health company, it was important for us to become members of NOAH and we are glad to have done so. We look forward to working with them and our fellow members to advance our shared mission in this sector, and to continue to elevate our industry in a global context.”.
Please contact us at noah@noah.co.uk or https://www.noah.co.uk/noah-contact-details/
Notes for Editors
For further information contact glennon@noah.co.uk
NOAH represents the UK animal health industry. Its aim is to promote the benefits of licensed medicines and solutions for the health and welfare of all animals.
Further information is available here https://www.petmedix.com